BLFSBIOLIFE SOLUTIONS INC

Nasdaq biolifesolutions.com


$ 23.08 $ -0.82 (-3.43 %)    

Monday, 09-Sep-2024 15:32:16 EDT
QQQ $ 453.86 $ 1.33 (0.29 %)
DIA $ 409.05 $ 1.73 (0.42 %)
SPY $ 545.98 $ 1.31 (0.24 %)
TLT $ 99.91 $ 0.53 (0.53 %)
GLD $ 231.37 $ 0.11 (0.05 %)
$ 23.79
$ 23.90
$ 23.11 x 100
-- x --
$ 23.08 - $ 23.97
$ 8.92 - $ 26.73
362,177
na
1.1B
$ 1.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-29-2020 03-31-2020 10-Q
19 05-15-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-15-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-11-2018 03-31-2018 10-Q
27 03-09-2018 12-31-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-11-2017 06-30-2017 10-Q
30 05-12-2017 03-31-2017 10-Q
31 03-15-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-16-2016 03-31-2016 10-Q
35 02-25-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-07-2015 03-31-2015 10-Q
39 03-12-2015 01-31-2015 10-K
40 11-06-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 craig-hallum-maintains-buy-on-biolife-solns-raises-price-target-to-30

Craig-Hallum analyst Matt Hewitt maintains BioLife Solns (NASDAQ:BLFS) with a Buy and raises the price target from $23 to $30.

 northland-capital-markets-maintains-outperform-on-biolife-solns-raises-price-target-to-28

Northland Capital Markets analyst Carl Byrnes maintains BioLife Solns (NASDAQ:BLFS) with a Outperform and raises the price t...

 biolife-solns-raises-fy24-sales-guidance-from-9550m-100m-to-99m-101m-vs-10579m

Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to...

 biolife-solns-q2-2024-adj-eps-005-beats-014-estimate-sales-28328m-beat-23946m-estimate

BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.14)...

 td-cowen-maintains-buy-on-biolife-solns-raises-price-target-to-26

TD Cowen analyst Steven Mah maintains BioLife Solns (NASDAQ:BLFS) with a Buy and raises the price target from $20 to $26.

 benchmark-upgrades-biolife-solns-to-buy-announces-25-price-target

Benchmark analyst Robert Wasserman upgrades BioLife Solns (NASDAQ:BLFS) from Hold to Buy and announces $25 price target.

 biolife-solutions-reiterates-guidance

2024 Revenue GuidanceBioLife Solutions is affirming its 2024 revenue guidance of $95.5 million to $100.0 million. This is based...

 biolife-solns-q1-2024-gaap-eps-022-beats-028-estimate-sales-1620m-miss-2601m-estimate

BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.28)...

 jefferies-initiates-coverage-on-biolife-solns-with-buy-rating-announces-price-target-of-22

Jefferies analyst Matthew Stanton initiates coverage on BioLife Solns (NASDAQ:BLFS) with a Buy rating and announces Price Ta...

 recap-biolife-solns-q4-earnings
Recap: BioLife Solns Q4 Earnings
02/29/2024 21:10:54

 biolife-solns-q4-2023-adj-eps-0210-beats-0340-estimate-sales-32732m-miss-33399m-estimate

BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.210) per share which beat the analyst consensus estimate of $(0.34...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION